Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Jazz Pharma Plc (JAZZ)

Jazz Pharma Plc (JAZZ)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 7,627,173
  • Shares Outstanding, K 56,573
  • Annual Sales, $ 1,891 M
  • Annual Income, $ 447,100 K
  • 60-Month Beta 1.18
  • Price/Sales 3.82
  • Price/Cash Flow 8.09
  • Price/Book 2.55

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate 3.61
  • Number of Estimates 5
  • High Estimate 3.68
  • Low Estimate 3.49
  • Prior Year 3.27
  • Growth Rate Est. (year over year) +10.40%

Price Performance

See More
Period Period Low Period High Performance
1-Month
133.38 +1.08%
on 02/21/20
152.24 -11.44%
on 01/22/20
-15.53 (-10.33%)
since 01/21/20
3-Month
133.38 +1.08%
on 02/21/20
154.24 -12.59%
on 12/24/19
-7.81 (-5.48%)
since 11/21/19
52-Week
116.52 +15.71%
on 10/14/19
154.24 -12.59%
on 12/24/19
+9.61 (+7.68%)
since 02/21/19

Most Recent Stories

More News
What Awaits Jazz Pharmaceuticals (JAZZ) in Q4 Earnings?

Progress of its pipeline candidates and launch of Sunosi is likely to have increased Jazz Pharmaceuticals (JAZZ) operating expenses in the fourth quarter. Xyrem likely to have continued strong demand trend....

AMAG : 9.50 (+0.85%)
IMMU : 18.06 (+0.17%)
JAZZ : 134.82 (-0.50%)
VCEL : 19.22 (+0.97%)
ImmunoGen (IMGN) Q4 Earnings & Sales Beat, Shares Rally

ImmunoGen (IMGN) reports fourth-quarter results with earnings and revenues beating estimates.

RHHBY : 44.0300 (+0.39%)
JAZZ : 134.82 (-0.50%)
IMGN : 5.41 (-3.05%)
ABBV : 94.96 (+0.77%)
PharmaMar and Jazz Pharmaceuticals Announce FDA Acceptance and Priority Review of New Drug Application for Lurbinectedin in Relapsed Small Cell Lung Cancer

PharmaMar (MSE:PHM) and Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announce that the U.S. Food and Drug Administration (FDA) accepted for filing with Priority Review the New Drug Application (NDA) seeking...

PHM : 46.41 (-0.56%)
JAZZ : 134.82 (-0.50%)
Jazz Pharmaceuticals to Report 2019 Fourth Quarter and Full Year Financial Results on February 25, 2020

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2019 fourth quarter and full year financial results on Tuesday, February 25, 2020, after the close of the financial markets....

JAZZ : 134.82 (-0.50%)
Jazz (JAZZ) Submits NDA for Xyrem Follow-On Candidate JZP-258 (Revised)

Jazz (JAZZ) files regulatory application seeking approval for JZP-258, a low sodium formulation of Xyrem, in the United States.

NVS : 96.76 (+0.49%)
AVDL : 9.40 (+32.02%)
JAZZ : 134.82 (-0.50%)
TEVA : 13.19 (-0.90%)
Why Jazz (JAZZ) Could Beat Earnings Estimates Again

Jazz (JAZZ) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

JAZZ : 134.82 (-0.50%)
Jazz (JAZZ) Submits NDA for Xyrem Follow-On Candidate JZP-258

Jazz (JAZZ) files regulatory application seeking approval for JZP-258, a low sodium formulation of Xyrem, in the United States.

NVS : 96.76 (+0.49%)
AVDL : 9.40 (+32.02%)
JAZZ : 134.82 (-0.50%)
TEVA : 13.19 (-0.90%)
Jazz Pharmaceuticals Submits New Drug Application for JZP-258 for Cataplexy and Excessive Daytime Sleepiness Associated with Narcolepsy

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration on January 21, 2020 seeking marketing approval for JZP-258,...

JAZZ : 134.82 (-0.50%)
PharmaMar and Jazz Pharmaceuticals Announce the U.S. License Agreement for Lurbinectedin is Effective with the Expiration of the HSR Waiting Period

PharmaMar (MSE:PHM) and Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announce that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended "HSR", with respect to the exclusive...

PHM : 46.41 (-0.56%)
JAZZ : 134.82 (-0.50%)
Jazz's (JAZZ) New Sleep Drug Sunosi Gets Approval in Europe

Jazz (JAZZ) receives approval for Sunosi as a treatment for excessive daytime sleepiness in narcolepsy or obstructive sleep apnea patients in Europe.

NVS : 96.76 (+0.49%)
AVDL : 9.40 (+32.02%)
JAZZ : 134.82 (-0.50%)
TEVA : 13.19 (-0.90%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakening short term outlook on maintaining the current direction.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Trade JAZZ with:

Business Summary

Jazz Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on identifying, developing and commercializing innovative products to meet unmet medical needs in neurology and psychiatry. Company's goal is to build a broad portfolio of products through a combination of internal development and...

See More

Key Turning Points

2nd Resistance Point 136.98
1st Resistance Point 135.90
Last Price 134.82
1st Support Level 133.56
2nd Support Level 132.30

See More

52-Week High 154.24
Fibonacci 61.8% 139.83
Fibonacci 50% 135.38
Last Price 134.82
Fibonacci 38.2% 130.93
52-Week Low 116.52

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar